IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma

Rob A. Cairns, Javeed Iqbal, François Lemonnier, Can Kucuk, Laurence De Leval, Jean Philippe Jais, Marie Parrens, Antoine Martin, Luc Xerri, Pierre Brousset, Li Chong Chan, Wing Chung Chan, Philippe Gaulard, Tak W. Mak

Research output: Contribution to journalArticlepeer-review

412 Scopus citations


Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in most grade 2 and 3 gliomas, secondary glioblastomas, and a subset of acute myelogenous leukemias but have not been detected in other tumor types. The mutations occur at specific arginine residues and result in the acquisition of a novel enzymatic activity that converts 2-oxoglutarate to D-2-hydroxyglutarate. This study reports IDH1 and IDH2 genotyping results from a set of lymphomas, which included a large set of peripheral T-cell lymphomas. IDH2 mutations were identified in approximately 20% of angioimmunoblastic T-cell lymphomas (AITLs), but not in other peripheral T-cell lymphoma entities. These results were confirmed in an independent set of AITL patients, where the IDH2 mutation rate was approximately 45%. This is the second common genetic lesion identified in AITL after TET2 and extends the number of neoplastic diseases where IDH1 and IDH2 mutations may play a role.

Original languageEnglish (US)
Pages (from-to)1901-1903
Number of pages3
Issue number8
StatePublished - Feb 23 2012

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma'. Together they form a unique fingerprint.

Cite this